CGEM vs VOR: stock comparison and AI forecast
Cullinan Therapeutics, Inc. (CGEM) and Vor Biopharma Inc. (VOR) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
CGEM Cullinan Therapeutics, Inc.
- Market Cap
- $1.01B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
VOR Vor Biopharma Inc.
- Market Cap
- $1.14B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- VOR is 1.1 times larger than CGEM by market capitalization ($1.14B against $1.01B).
- Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | CGEM | VOR |
|---|---|---|
| Market Cap | $1.01B | $1.14B |
| P/B Ratio | 3.15x | – |
| Book Value/Share | $5.00 | – |
Profitability & Margins
| Metric | CGEM | VOR |
|---|---|---|
| ROE | -63.6% | – |
| ROA | -56.3% | – |
| ROIC | -68.6% | -38.6% |
| Tax Rate | 0.0% | – |
Financial Health
| Metric | CGEM | VOR |
|---|---|---|
| Current Ratio | 8.42x | 13.50x |
| D/E Ratio | 0.13x | – |
| Financial Leverage | 1.13x | – |
| Interest Coverage | -1019.0x | – |
| Working Capital | $301M | – |
Cash Flow
| Metric | CGEM | VOR |
|---|---|---|
| Operating Cash Flow | -$159M | – |
Income Statement
| Metric | CGEM | VOR |
|---|---|---|
| Operating Income | -$222M | – |
| Net Income | -$205M | – |
| R&D Expense | $171M | – |
Dividend & Shareholder Information
| Metric | CGEM | VOR |
|---|---|---|
| Shares Outstanding | 64M | 59M |
CGEM vs VOR: stock comparison and AI forecast
Which is bigger, CGEM or VOR?
VOR is 1.1 times larger than CGEM by market capitalization ($1.14B against $1.01B).
Which one does Intratio's AI model rank higher, CGEM or VOR?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.